Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Nanae Sugasaki"'
Autor:
Hiromi Tomono, Hirokazu Taniguchi, Minoru Fukuda, Takaya Ikeda, Seiji Nagashima, Kazumasa Akagi, Sawana Ono, Yasuhiro Umeyama, Midori Shimada, Hiroshi Gyotoku, Shinnosuke Takemoto, Yasushi Hisamatsu, Ryotaro Morinaga, Ryuta Tagawa, Ryosuke Ogata, Yosuke Dotsu, Hiroaki Senju, Hiroshi Soda, Katsumi Nakatomi, Fumiko Hayashi, Nanae Sugasaki, Akitoshi Kinoshita, Hiroshi Mukae
Publikováno v:
Thoracic Cancer, Vol 14, Iss 28, Pp 2890-2894 (2023)
Abstract Introduction Combined treatment using anti‐programmed death‐ligand 1 antibody (anti‐PD‐L1) and platinum‐etoposide is the current standard first‐line treatment for patients with extensive‐stage (ES) small cell lung cancer (SCLC)
Externí odkaz:
https://doaj.org/article/58002b57502d40c3b42c6726aa5a9340
Autor:
Kanako Sakaeda, Koji Kurose, Yuki Matsumura, Satoshi Muto, Minoru Fukuda, Nanae Sugasaki, Masaaki Fukuda, Shinnosuke Takemoto, Hirokazu Taniguchi, Takeshi Masuda, Katsuhiko Shimizu, Yuki Kataoka, Yasuhiro Irino, Yumiko Sakai, Yusuke Atarashi, Masatoshi Yanagida, Noboru Hattori, Hiroshi Mukae, Masao Nakata, Eiichiro Kanda, Toru Oga, Hiroyuki Suzuki, Mikio Oka
Publikováno v:
Cancer Treatment and Research Communications, Vol 40, Iss , Pp 100830- (2024)
Background: NY-ESO-1 and XAGE1 cancer/testis antigens elicit humoral and cellular immune responses in NSCLC patients. We aimed to predict clinical benefit with ICI monotherapy, using an automated immunoassay of NY-ESO-1/XAGE1 antibodies (Abs). Method
Externí odkaz:
https://doaj.org/article/fa49acdde51b426e87156baacb0661b1
Autor:
Shinnosuke Takemoto, Kazumasa Akagi, Sawana Ono, Hiromi Tomono, Noritaka Honda, Takayuki Suyama, Yasuhiro Umeyama, Yosuke Dotsu, Hirokazu Taniguchi, Daiki Ogawara, Hiroaki Senju, Hiroshi Gyotoku, Nanae Sugasaki, Hiroyuki Yamaguchi, Katsumi Nakatomi, Minoru Fukuda, Hiroshi Mukae
Publikováno v:
Thoracic Cancer, Vol 12, Iss 17, Pp 2300-2306 (2021)
Abstract Background S‐1 and pemetrexed (PEM) are key treatments for non‐small cell lung cancer (NSCLC). However, the mechanism of anticancer activity of S‐1 and PEM is similar. Cross‐resistance between S‐1 and PEM is of concern. This explor
Externí odkaz:
https://doaj.org/article/602db2692a2a4097822cef7b5d6f304e
Autor:
Hirokazu Taniguchi, Hiroyuki Yamaguchi, Yosuke Dotsu, Midori Shimada, Hiroshi Gyotoku, Hiroaki Senju, Shinnosuke Takemoto, Takeshi Kitazaki, Masaaki Fukuda, Daiki Ogawara, Hiroshi Soda, Katsumi Nakatomi, Nanae Sugasaki, Akitoshi Kinoshita, Seiji Nagashima, Takaya Ikeda, Yoichi Nakamura, Noriho Sakamoto, Yasushi Obase, Minoru Fukuda, Hiroshi Mukae
Publikováno v:
Thoracic Cancer, Vol 10, Iss 9, Pp 1764-1769 (2019)
Background The first‐line treatment for squamous cell lung cancer (SCC) has not necessarily been established; however, our previous exploratory study suggested that the combination of nedaplatin and amrubicin would be a promising treatment approach
Externí odkaz:
https://doaj.org/article/a4c5fc3cc43545d99dee8994a4d745d0
Autor:
Hiroshi Mukae, Noritaka Honda, Nanae Sugasaki, Hiromi Tomono, Shinnosuke Takemoto, Yasuhiro Umeyama, Hiroyuki Yamaguchi, Sawana Ono, Daiki Ogawara, Katsumi Nakatomi, Hiroaki Senju, Kazumasa Akagi, Yosuke Dotsu, Hirokazu Taniguchi, Hiroshi Gyotoku, Takayuki Suyama, Minoru Fukuda
Publikováno v:
Thoracic Cancer
Thoracic Cancer, Vol 12, Iss 17, Pp 2300-2306 (2021)
Thoracic Cancer, Vol 12, Iss 17, Pp 2300-2306 (2021)
Background S‐1 and pemetrexed (PEM) are key treatments for non‐small cell lung cancer (NSCLC). However, the mechanism of anticancer activity of S‐1 and PEM is similar. Cross‐resistance between S‐1 and PEM is of concern. This exploratory stu
Autor:
Kanako Sakaeda, Koji Kurose, Minoru Fukuda, Nanae Sugasaki, Akitoshi Kinoshita, Takashi Kitazaki, Masaaki Fukuda, Takeshi Masuda, Noboru Hattori, Yusuke Atarashi, Yumiko Sakai, Yasuhiro Irino, Mami Yamaki, Toshiyuki Sato, Hiroshi Mukae, Toru Oga, Mikio Oka
Publikováno v:
Cancer Immunology Research. 10:A61-A61
Introduction: Immunotherapy with immune checkpoint inhibitors (ICI) is the standard of care for advanced non-small-cell lung cancer (NSCLC) without driver gene alterations. However, survival benefits with ICI are limited to a small subset of NSCLC pa
Autor:
Takaya Ikeda, Katsumi Nakatomi, Akitoshi Kinoshita, Nanae Sugasaki, Hiroshi Gyotoku, Yosuke Dotsu, Noriho Sakamoto, Seiji Nagashima, Daiki Ogawara, Midori Shimada, Yasushi Obase, Hiroaki Senju, Hirokazu Taniguchi, Yoichi Nakamura, Masaaki Fukuda, Takeshi Kitazaki, Minoru Fukuda, Hiroshi Mukae, Shinnosuke Takemoto, Hiroyuki Yamaguchi, Hiroshi Soda
Publikováno v:
Thoracic Cancer, Vol 10, Iss 9, Pp 1764-1769 (2019)
Thoracic Cancer
Thoracic Cancer
BACKGROUND The first-line treatment for squamous cell lung cancer (SCC) has not necessarily been established; however, our previous exploratory study suggested that the combination of nedaplatin and amrubicin would be a promising treatment approach f
Autor:
Tetsuya Kawano, Katsuhisa Omagari, Chizu Fukushima, Akitoshi Kinoshita, Nanae Sugasaki, Yasushi Obase, Masaki Yamakawa, Yasuhiro Umeyama, Susumu Fukahori, Hiroshi Mukae
Publikováno v:
The American Journal of Case Reports
BACKGROUND Focal nodular hyperplasia (FNH) of the liver is a rare benign nodular lesion that arises in women of reproductive age. Although a role of female hormones has been suggested, their influence on the course of FNH has remained controversial.
Autor:
Susumu Fukahori, Tetsuya Kawano, Yasushi Obase, Yasuhiro Umeyama, Nanae Sugasaki, Akitoshi Kinoshita, Chizu Fukushima, Masaki Yamakawa, Katsuhisa Omagari, Hiroshi Mukae
Publikováno v:
American Journal of Case Reports; 7/30/2019, Vol. 20, p1124-1127, 4p
Autor:
Takaya Ikeda, Takuya Yamazaki, Katsumi Nakatomi, Nanae Sugasaki, Yosuke Dotsu, Minoru Fukuda, Midori Shimada, Nobuyuki Hayashi, Yoichi Nakamura, Hiroshi Mukae, Hiroyuki Yamaguchi
Publikováno v:
Journal of Clinical Oncology. 35:e20023-e20023
e20023 Background: Amrubicin and cisplatin is one of active regimens for patients with extensive-disease small cell lung cancer (ED-SCLC). Combined modality of combination chemotherapy and concurrent thoracic radiotherapy has been recognized as stand